Leqembi posts record $184M in Q2, its third straight quarter of growth, as Biogen lifts full-year guidance and folds in Apellis.
Leqembi, the anti-amyloid Alzheimer’s drug from Eisai and Biogen, recorded $184 million in global sales in the second quarter, Biogen said Wednesday morning.
It’s the …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Biogen leans on newly acquired Apellis' Empaveli and Syfovre to offset Leqembi's disappointing Alzheimer's sales ahead of Q2…
After doubling sales of its Biogen-partnered Alzheimer’s disease med Leqembi in its 2025 fiscal year, Eisai figures the crawl to…
Eisai (ESAIY) and Biogen (BIIB) announced that new data presented at the Alzheimer’s Association International Conference, AAIC,…
The US FDA approved an at-home starting dose for Eisai and Biogen's Alzheimer's drug. This new subcutaneous formulation allows…
FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pipeline progress.
